Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Date:12/13/2011

CAMBRIDGE, Mass., Dec. 13, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with cetuximab (Erbitux®) and irinotecan (Camptosar®) in patients with advanced cancers.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab and irinotecan in patients with advanced colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, or other types of solid tumors that depend on epidermal growth factor receptor (EGFR) activity. Multiple centers across the United States are expected to participate in this study. The first patient was enrolled at the Huntsman Cancer Institute at the University of Utah in Salt Lake City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... All-Star Insurance of Northeast TX has ... of their local community. The agency pledges to select a new beneficiary every ... to bring awareness to important local causes with fundraising and other support, by ...
(Date:5/4/2016)... ... 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge ... Wisdom tooth removal, a common dental procedure, is performed for many adolescents and young ... resulting in risks of complications. By providing wisdom tooth removal surgery at their office, ...
(Date:5/4/2016)... NC (PRWEB) , ... May 04, 2016 , ... Francesca ... N.C., changed her life forever with a same-day LASIK procedure at Christenbury ... poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office ...
(Date:5/4/2016)... Wylie, TX (PRWEB) , ... May 04, 2016 ... ... new Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in ... in Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included ...
(Date:5/4/2016)... Boulder City, Nevada (PRWEB) , ... May 04, 2016 , ... ... against bladder infections. Bladder infections, also called UTIs, have plagued people since the ... medicine, millions of women get bladder infections every year. It's not just a matter ...
Breaking Medicine News(10 mins):